Compare Hims and Hers Health Inc (HIMS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs IDEXX Laboratories, Inc. — how do they compare? Hims and Hers Health Inc trades at $30.2 (market cap $6.55B), while IDEXX Laboratories, Inc. trades at $519.54 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.2× Hims and Hers Health Inc's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| HIMS | IDXX | |
|---|---|---|
Market Cap | $6.55B | $40.43B |
Volume | 14,842,814 | 692,164 |
Sector | Health | Health |
52-Week High | $62.76 | $766.68 |
52-Week Low | $14.52 | $504.70 |
Typical Hold Time | 21 Days | 46 Days |
Enterprise Value | $7.25B | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.
The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
